143 related articles for article (PubMed ID: 37708348)
1. Association of Receipt of Systemic Treatment for Melanoma With Insurance Type in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Haynes AB; Pignone MP
Med Care; 2023 Dec; 61(12):829-835. PubMed ID: 37708348
[TBL] [Abstract][Full Text] [Related]
2. Association of Delays in Surgery for Melanoma With Insurance Type.
Adamson AS; Zhou L; Baggett CD; Thomas NE; Meyer AM
JAMA Dermatol; 2017 Nov; 153(11):1106-1113. PubMed ID: 28979974
[TBL] [Abstract][Full Text] [Related]
3. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
4. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
5. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Treatment Disparities: A Texas Cancer Registry Analysis of Patients with Cutaneous Melanoma.
Ramirez F; Alvarado L; Dwivedi A; Chacon J
J Immigr Minor Health; 2024 Feb; 26(1):23-33. PubMed ID: 37615821
[TBL] [Abstract][Full Text] [Related]
7. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.
Bagley AF; Anscher MS; Choi S; Frank SJ; Hoffman KE; Kuban DA; McGuire SE; Nguyen QN; Chapin B; Aparicio A; Pezzi TA; Smith GL; Smith BD; Hess K; Tang C
JAMA Netw Open; 2020 Mar; 3(3):e201255. PubMed ID: 32191331
[TBL] [Abstract][Full Text] [Related]
8. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
[TBL] [Abstract][Full Text] [Related]
9. Disparities in Systemic Treatment Use in Advanced-stage Non-Small Cell Lung Cancer by Source of Health Insurance.
Maguire FB; Morris CR; Parikh-Patel A; Cress RD; Keegan THM; Li CS; Lin PS; Kizer KW
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1059-1066. PubMed ID: 30842132
[TBL] [Abstract][Full Text] [Related]
10. Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance.
Warren JL; Butler EN; Stevens J; Lathan CS; Noone AM; Ward KC; Harlan LC
J Clin Oncol; 2015 Feb; 33(4):312-8. PubMed ID: 25534387
[TBL] [Abstract][Full Text] [Related]
11. Association of surgical interval and survival among hospital and non-hospital based patients with melanoma in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Pignone MP
Arch Dermatol Res; 2021 Oct; 313(8):653-661. PubMed ID: 33098016
[TBL] [Abstract][Full Text] [Related]
12. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.
Amini A; Rusthoven CG; Waxweiler TV; Jones BL; Fisher CM; Karam SD; Raben D
J Am Acad Dermatol; 2016 Feb; 74(2):309-16. PubMed ID: 26670715
[TBL] [Abstract][Full Text] [Related]
13. Insurance type influences the use of drug-eluting stents.
Gaglia MA; Torguson R; Xue Z; Gonzalez MA; Collins SD; Ben-Dor I; Syed AI; Maluenda G; Delhaye C; Hanna N; Wakabayashi K; Kaneshige K; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
JACC Cardiovasc Interv; 2010 Jul; 3(7):773-9. PubMed ID: 20650440
[TBL] [Abstract][Full Text] [Related]
14. Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women.
Doll KM; Meng K; Gehrig PA; Brewster WR; Meyer AM
Am J Obstet Gynecol; 2016 Oct; 215(4):447.e1-447.e13. PubMed ID: 27130238
[TBL] [Abstract][Full Text] [Related]
15. Association of insurance status with timing of hemodialysis access placement.
Lazar AN; Johnson AP; Morrissey NJ
J Vasc Surg; 2021 Oct; 74(4):1309-1316.e2. PubMed ID: 34186164
[TBL] [Abstract][Full Text] [Related]
16. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
[TBL] [Abstract][Full Text] [Related]
17. Distance to a Plastic Surgeon and Type of Insurance Plan Are Independently Predictive of Postmastectomy Breast Reconstruction.
Roughton MC; DiEgidio P; Zhou L; Stitzenberg K; Meyer AM
Plast Reconstr Surg; 2016 Aug; 138(2):203e-211e. PubMed ID: 27465180
[TBL] [Abstract][Full Text] [Related]
18. Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival.
Moon AM; Sanoff HK; Chang Y; Lund JL; Barritt AS; Hayashi PH; Stitzenberg KB
J Natl Compr Canc Netw; 2021 Feb; 19(3):285-293. PubMed ID: 33578376
[TBL] [Abstract][Full Text] [Related]
19. Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
Olateju OA; Zeng Z; Thornton JD; Mgbere O; Essien EJ
BMC Cancer; 2023 Jul; 23(1):655. PubMed ID: 37442992
[TBL] [Abstract][Full Text] [Related]
20. Validity of breast cancer surgery treatment information in a state-based cancer registry.
Roberson ML; Nichols HB; Wheeler SB; Reeder-Hayes KE; Olshan AF; Baggett CD; Robinson WR
Cancer Causes Control; 2022 Feb; 33(2):261-269. PubMed ID: 34783925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
